Business Context and Reporting Period
This Form 8-K Current Report, filed on September 25, 2007, covers events occurring between September 19 and September 25, 2007, for Nephros, Inc. The filing details a significant capital restructuring and financing transaction involving the issuance of new secured convertible notes, the exchange of existing debt, and a complete overhaul of the Board of Directors.
Key Financial Metrics and Capital Structure
- New Debt Issuance: The Company sold approximately $12.7 million in principal amount of Series A 10% Secured Convertible Notes due 2008 to new investors.
- Debt Exchange: Existing investors exchanged approximately $5.6 million in principal and accrued interest of 6% Secured Convertible Notes due 2012 for $5.3 million in principal of new Series B 10% Secured Convertible Notes due 2008.
- Total New Notes: The aggregate principal amount of the new debt instruments (Series A and Series B) is approximately $18.0 million.
- Interest Rate: New Notes accrue interest at 10% per annum, compounded annually.
- Security: The New Notes are secured by a first lien and security interest on all of Nephros' assets.
- Conversion Terms: Upon stockholder approval, the notes will convert into common stock at a price of $0.706 per share. Series A notes also include warrants to purchase 50% of the converted shares at $0.90 per share.
- Transaction Costs: Placement agents received an 8% cash fee on the face amount of the Purchased Notes ($12.7 million) plus warrants for 10% of the shares issuable upon conversion.
Material Changes Versus Prior Period
The filing represents a material shift in the Company's capital structure and governance, distinct from prior periods:
- Debt Refinancing: The Company replaced higher-maturity, lower-interest debt (6% due 2012) with shorter-term, higher-interest debt (10% due 2008) to secure immediate liquidity and investor support.
- Board Composition: Four directors, including Executive Chairman William J. Fox, resigned effective September 19, 2007. Two new directors, Paul A. Mieyal and Arthur H. Amron (affiliates of the lead investor, Lambda Investors LLC), were appointed.
- Authorized Capital: Stockholders approved an amendment to increase authorized common stock to 60 million shares to accommodate the conversion of the new notes.
Guidance, Outlook, Risks, and Contingencies
- Stockholder Approval Requirement: The automatic conversion of the New Notes into equity is contingent upon stockholder approval, which becomes effective 20 days after the definitive Schedule 14C is sent. The Company must file a preliminary Schedule 14C within 15 business days of the closing.
- Registration Rights and Penalties: The Company must file a resale registration statement within 60 days of the definitive Schedule 14C and have it declared effective within 240 days. Failure to do so triggers liquidated damages of 1% of the conversion amount per 30-day period (increasing to 2% after ten periods) plus 15% annual interest.
- Investor Rights and Conflicts: Under the Investor Rights Agreement, the lead investor (Lambda) has the right to engage in competing business activities and is not liable for breach of fiduciary duty regarding such activities. Lambda also has the right to nominate directors and convene board meetings.
- Events of Default: The New Notes contain strict default provisions, including failure to pay, bankruptcy, breach of covenants, or incurrence of additional indebtedness without Lambda's approval. Default allows for immediate acceleration of the debt.
- Executive Departure: William J. Fox received a separation package of $142,500 paid over six months and accelerated vesting of 56,250 stock options.
Investor Verification Checklist
- Verify the status of the Schedule 14C filing and the timeline for stockholder approval to confirm the conversion of debt to equity.
- Review the definitive Registration Rights Agreement to monitor the 240-day deadline for the effectiveness of the resale registration statement and potential liquidated damages.
- Assess the impact of the 10% interest rate and 2008 maturity date on the Company's near-term liquidity and cash flow requirements.
- Examine the Investor Rights Agreement for specific limitations on the Company's ability to pursue corporate opportunities or compete with the lead investor.
- Confirm the final composition of the Board of Directors and the extent of control held by Lambda Investors LLC.